` BDSX (Biodesix Inc) vs S&P 500 Comparison - Alpha Spread

BDSX
vs
S&P 500

Over the past 12 months, BDSX has underperformed S&P 500, delivering a return of -84% compared to the S&P 500's 10% growth.

Stocks Performance
BDSX vs S&P 500

Loading
BDSX
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
BDSX vs S&P 500

Loading
BDSX
S&P 500
Difference
www.alphaspread.com

Performance By Year
BDSX vs S&P 500

Loading
BDSX
S&P 500
Add Stock

Competitors Performance
Biodesix Inc vs Peers

Biodesix Inc
Glance View

Market Cap
38.4m USD
Industry
Health Care

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The company is headquartered in Boulder, Colorado and currently employs 218 full-time employees. The company went IPO on 2020-10-28. The firm uses its artificial intelligence (AI) platform, Diagnostic Cortex, to discover, develop, and commercialize solutions for clinical unmet needs, with a primary focus on lung disease. In addition to its diagnostic tests, it provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development and commercialization of companion diagnostics. The firm offers blood-based lung cancer tests across the lung cancer continuum of care, including Nodify XL2 and Nodify CDT tests, and GeneStrat and VeriStrat tests. The firm also offers three SARS-CoV-2 tests under the Biodesix WorkSafe testing program, such as Bio-Rad SARS-CoV-2 ddPCR test, Platelia SARS-CoV-2 Total Ab test and cPass SARS-CoV-2 Neutralization Antibody Test.

BDSX Intrinsic Value
2.042 USD
Undervaluation 87%
Intrinsic Value
Price
Back to Top